Causative Pathogen Dictates Optimal Duration of Antimicrobial Therapy for Ventilator-Associated Pneumonia in Trauma Patients
Authors:
- Louis J. MagnottiLMLouis J. Magnotti
- Martin A. CroceMCMartin A. Croce
- Ben L. ZarzaurBZBen L. Zarzaur
- Joseph M. SwansonJSJoseph M. Swanson
- Christopher G. WoodCWChristopher G. Wood
- Jordan A. WeinbergJWJordan A. Weinberg
- Timothy C. FabianTFTimothy C. Fabian
- 1 April 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 212 (4) , 476-484
Abstract
Recent ventilator-associated pneumonia (VAP) guidelines recommend considering abbreviated therapy in patients with non-Pseudomonas aeruginosa VAP if clinical signs resolve. However, using an arbitrary day cutoff or clinical signs can be suboptimal for some, especially multiply injured patients, resulting in relapse and/or antibiotic resistance. Previously, we showed that repeat bronchoalveolar lavage (BAL) could guide antimicrobial duration for community-acquired VAP in trauma patients. The purpose of this study was to determine the appropriate duration of antimicrobial therapy for VAP in trauma patients secondary to hospital-acquired pathogens. Patients with VAP secondary to MRSA, Pseudomonas aeruginosa (PA), Acinetobacter baumannii (AB), Stenotrophomonas maltophilia (SM), or Enterobacteriaceae (ENB) during 6 years were evaluated. All received empiric antimicrobial therapy based on duration of ICU stay. Therapy was tailored based on culture data. Repeat BAL was performed on day 4 of appropriate therapy. Microbiological resolution was defined as ≤10(3) colony-forming units/mL. Recurrence was defined as ≥10(5) colony-forming units/mL on subsequent BAL performed within 2 weeks after completion of appropriate therapy. Six hundred and fifty-nine patients were identified. Seventy-seven percent of patients underwent repeat BAL: 96 with MRSA, 100 with AB, 139 with PA, 50 with SM, and 120 with ENB. The majority of patients with MRSA or PA achieved microbiological resolution after 14 days. Nearly 60% of patients with AB, SM, or ENB achieved microbiological resolution after 10 days. Overall recurrence was 2%. Repeat BAL provides objective evidence for VAP resolution in the face of potentially confounding clinical factors. Hospital-acquired VAP can be managed effectively by a defined course of therapy with a low recurrence. Duration of antimicrobial therapy for VAP in trauma patients should be dictated by the causative pathogen.Keywords
This publication has 20 references indexed in Scilit:
- Evaluation of a Clinical Pathway for Ventilator-Associated Pneumonia: Changes in Bacterial Flora and the Adequacy of Empiric Antibiotics over a Three-Year PeriodSurgical Infections, 2005
- Inadequate Antimicrobial Treatment: An Important Determinant of Outcome for Hospitalized PatientsClinical Infectious Diseases, 2000
- The Attributable Morbidity and Mortality of Ventilator-Associated Pneumonia in the Critically Ill PatientAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Utility of Gram's Stain and Efficacy of Quantitative Cultures for Posttraumatic PneumoniaAnnals of Surgery, 1998
- Impact of BAL Data on the Therapy and Outcome of Ventilator-Associated PneumoniaChest, 1997
- Nosocomial pneumonia and mortality among patients in intensive care units1996
- Using Bronchoalveolar Lavage to Distinguish Nosocomial Pneumonia from Systemic Inflammatory Response SyndromeThe Journal of Trauma: Injury, Infection, and Critical Care, 1995
- The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory CommitteeJAMA, 1995
- Role of bronchoalveolar lavage in mechanically ventilated patients with suspected pneumoniaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1994
- Evaluation of Clinical Judgment in the Identification and Treatment of Nosocomial Pneumonia in Ventilated PatientsChest, 1993